June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches

Following Brain Cancer Awareness Month, June marks Brain and Spine Metastasis Awareness Month, a critical time to raise awareness about the increasing incidence of brain and spinal metastases, their impact on prognosis and quality of life, and the growing list of treatment options now available or under development.

At Plus Therapeutics, we are actively working to address one of the most challenging and life-threatening forms of central nervous system (CNS) cancerLeptomeningeal Metastases (LM)—through our ongoing ReSPECT-LM clinical trial.

What Are Leptomeningeal Metastases?

Leptomeningeal Metastases occur when cancer cells spread from solid tumors—most commonly breast cancer, lung cancer, and melanoma—into the cerebrospinal fluid (CSF) and the leptomeninges, the membranes surrounding the brain and spinal cord. LM is a rare but devastating complication of metastatic cancer with limited treatment options and a historically poor prognosis.

Our ReSPECT-LM clinical trial is focused on evaluating a targeted radiotherapeutic approach to treat LM and improve outcomes for patients with this serious condition.

Download our Patient Guide to Leptomeningeal Metastases to learn more: View Guide

Partnering for Awareness and Support

We are proud to stand alongside organizations like:

  • Leptomeningeal Cancer Foundation
  • American Brain Tumor Association
  • Susan G. Komen
  • Living Beyond Breast Cancer
  • LUNGevity Foundation
  • LiveLung
  • Metastatic Breast Cancer Alliance
  • AIM at Melanoma

These groups work tirelessly to support patients, caregivers, and researchers driving innovation in the field of brain and spine metastases.

To learn more about our research and clinical trials, visit: www.plustherapeutics.com

#BrainandSpineMetastasisAwarenessMonth #LeptomeningealMetastases #BrainSpineMetastasis #CNSCancer #ClinicalTrials #ReSPECTLM #BrainCancer #BreastCancer #LungCancer #Melanoma #Radiotherapeutics #MetsGetsAwareness #PlusTherapeutics #PSTV #CancerResearch #MetastaticCancer